Rho-kinase inhibitor targeting the liver prevents liver fibrosis without major systemic adversity in rats
Project/Area Number |
26861078
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Digestive surgery
|
Research Institution | Hiroshima University |
Principal Investigator |
|
Project Period (FY) |
2014-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 肝線維化 / 星細胞 / リポソーム / DDS / Rhoキナーゼ阻害剤 / 肝星細胞 / Drug Delivery System |
Outline of Final Research Achievements |
Rho-kinase (ROCK) inhibitors improve liver blood flow after ischemia/reperfusion (IR) injury or improve liver fibrosis, by preventing the activation of hepatic stellate cell (HSC). However, the systemic administration of ROCK inhibitors causes severe hypotension; therefore, liver-specific ROCK inhibition is required. Here, we tested vitamin A coupled liposomes carrying the ROCK inhibitor for targeted HSCs in rat IR model and liver fibrosis model. Liposomal ROCK inhibitor was 100-fold more effective in inhibiting HSC activation than free ROCK inhibitor without major systemic adversity in rats.
|
Report
(3 results)
Research Products
(4 results)
-
[Journal Article] Rho-kinase inhibitor targeting the liver prevents ischemia/reperfusion injury in the steatotic liver without major systemic adversity in rats2015
Author(s)
Kuroda, Shintaro Tashiro, Hirotaka Kimura, Yasuhiro Hirata, Kaori Tsutada, Misaki Mikuriya, Yoshihiro Kobayashi, Tsuyoshi Amano, Hironobu Tanaka, Yuka Ohdan, Hideki
-
Journal Title
Liver Transpl
Volume: 21
Pages: 123
DOI
Related Report
Peer Reviewed
-
-
-